FDA Oncology Announcements

Asparagine-specific enzyme × Lymphoid × Clear all

5 Announcements

FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)

Drug: Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) · Asparagine-specific enzyme
Condition: Lymphoid

FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma

Drug: Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) · Asparagine-specific enzyme
Conditions: LymphoidOther hematologic neoplasm

FDA approves longer-acting calaspargase pegol-mknl for ALL

Drug: ASPARLAS (calaspargase pegol-mknl) · Asparagine-specific enzyme
Condition: Lymphoid

asparaginase Erwinia chrysanthemi

Drug: Erwinaze (asparaginase erwinia chrysanthemi) · Asparagine-specific enzyme
Condition: Lymphoid

FDA Approves pegaspargase (Oncaspar, Enzon Pharmaceuticals, Inc) for the first-line treatment of patients with acute lymphoblastic leukemia

Drug: Oncaspar (pegaspargase) · Asparagine-specific enzyme
Conditions: LymphoidOther hematologic neoplasm